DESITIN PHARMA A/S: Financial statements 2019
CVR: 19389006
Source: annual report 2019, Danish Business Authority
01/10/2018 – 30/09/2019
DESITIN PHARMA A/S (CVR 19389006) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 5,696,243 and a net result of DKK 540,753 compared with DKK 1,515,573 the year before. That is a decrease of 5.3% compared with the year before. Equity in the 2019 report amounted to DKK 5,658,835. The solvency ratio was 77.7%. The company had 4 employees in the financial year.
- Gross Profit
- DKK 5,696,243
- Profit/Loss
- DKK 540,753
- Equity
- DKK 5,658,835
- Total Assets
- DKK 7,286,576
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 5.7M | 541K | 5.7M | 4 |
| 2018 | - | 6M | 1.5M | 5.1M | - |
| 2017 | - | 4.6M | 630K | 3.6M | - |
| 2016 | - | 5.6M | 1.2M | 3.7M | - |
| 2015 | - | 7.4M | 2.4M | 3.7M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of July 15, 2019, Alexander Arnkværn Berg has joined the board of directors of DESITIN PHARMA A/S.
As of July 15, 2019, Tina Nørgaard has left the board of directors of DESITIN PHARMA A/S.
As of July 15, 2019, Alexander Arnkværn Berg is registered as director of DESITIN PHARMA A/S.
As of July 15, 2019, Tina Nørgaard has stepped down as adm. dir. of DESITIN PHARMA A/S.
About DESITIN PHARMA A/S
DESITIN PHARMA A/S is a Danish company of the type Aktieselskab based in København V, founded in 1996. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Eli Lønne. The board consists of Philipp Andreas Bloching (chair), Eli Lønne and Oliver Christoph. The company is owned by Desitin Arzneimittel GmbH. The company has 1 employee (2026). In 2026, the company reported a gross profit of DKK 3,230,179 and a net result of DKK 350,332 compared with DKK 288,733 the year before. Equity in the 2026 report amounted to DKK 7,394,472.